Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 19/20 | 0.68 |
| ▸ | SOAT2 | O75908 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.45 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410404 | 1.00 | DGAT1 (0.68) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL10197151 | 0.99 | DGAT1 (0.69) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL10260835 | 0.99 | DGAT1 (0.69) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL406025 | 0.90 | DGAT1 (0.66) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL406024 | 0.90 | DGAT1 (0.66) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL462605 | 0.87 | DGAT1 (0.58) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL462604 | 0.87 | DGAT1 (0.58) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL10261211 | 0.87 | DGAT1 (0.58) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL13190605 | 0.87 | DGAT1 (0.50) | DGAT1 | |
| SCHEMBL407801 | 0.84 | DGAT1 (0.73) | DGAT1SOAT2CYP2C9SOAT1DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010107768-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885SOAT2 9/4885CYP2C9 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.